Rentschler Increases Capacity
By

By
Rentschler Biotechnologie, a Laupheim, Germany-based contract development and manufacturing organization for biopharmaceuticals, has opened a new single-use bioreactor at the company’s site in Laupheim with a capacity of 2,000 liters.…

CoreRx Adds Capacity
By

By
CoreRx, a Clearwater, Florida-based contract development manufacturing organization, has announced plans to continue expanding its drug product development and manufacturing capabilities at its site in Clearwater. The expansion will include…

AbbVie and Mylan Lead Pipeline News
By

By
A roundup of the latest market developments from the pipelines of the pharmaceutical majors and other related news, featuring news from AbbVie and Mylan. Editor’s Note: This article is updated…

Amgen, Pfizer, and Teva Lead Drug Approvals
By

By
A roundup of the latest drug approvals, including from the pharmaceutical majors, featuring news from Amgen, Pfizer, and Teva. Editor’s Note: This article is updated on a continuous basis for news…

Gilead Pays $200-Million Milestone for Liver-Disease Drug
By

By
Gilead Sciences has made a $200-million milestone payment to Nimbus Therapeutics, a biotechnology company headquartered in Cambridge, Massachusetts, related to Gilead’s allosteric acetyl-CoA carboxylase (ACC) inhibitor program with drug candidate…

Medivir to Acquire Oncology Programs in $238-Million Deal
By

By
Medivir, a Stockholm, Sweden-based pharmaceutical company, has agreed to acquire two clinical-stage oncology programs from Tetralogic Pharmaceuticals, a Malvern, Pennsylvania-based biopharmaceutical company in a deal valued up to $238 million. The…

Celldex Acquires Immuno-Oncology Portfolio in $235-Million Deal
By

By
Celldex Therapeutics, a Hampton, New Jersey-based pharmaceutical company, has agreed to acquire Kolltan Pharmaceuticals, a privately held clinical-stage company based in New Haven, Connecticut focused primarily in oncology, to boost…

Avacta in CAR-T Cell Therapy Pact
By

By
Avacta, a Wetherby, UK-based biotherapeutics and research reagents company, has formed a research collaboration with Memorial Sloan Kettering Cancer Center (MSK) to evaluate the use of Avacta’s Affimer technology in…

BMS Gives Pain-Drug Rights to Partner
By

By
Bristol-Myers Squibb has given the research, development, and commercialization rights to LX9211 (BMS-986176), an orally administered small molecule being developed to treat neuropathic pain that the company is jointly developing…

Valeant Evaluates Divestitures
By

By
Valeant Pharmaceuticals International has confirmed that it is evaluating certain divestitures, including of Salix Pharmaceuticals, a Raleigh, North Carolina-headquartered specialty pharmaceutical company that Valeant acquired in 2014 for approximately $15.8…